Abbisko Therapeutics of Shanghai closed a $28 million A round to develop its preclinical portfolio of three oncology drug candidates. The company focuses on innovative small molecule immunomodulators for cancers prevalent in Asia, using a combination of in-house R&D and outside CROs. The investors were Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital and TF Capital. Abbisko, which is less than a year old, is located in Zhangjiang Hi-Tech Park, and is led by veteran pharma executives with experience in the west and China.
